/DOCS
DOCS Stock - Doximity, Inc.
Healthcare|Medical - Healthcare Information ServicesNYSE
$43.65+0.37%
+$0.16 (+0.37%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.65
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+61.7%upside
Target: $70.58
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DOCS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$43.21 – $44.09
TARGET (TP)$70.60
STOP LOSS$40.16
RISK/REWARD1:7.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.38
52W High$85.21
52W Low$43.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $570.40M | $475.42M | $419.05M | $343.55M | $206.90M |
| Gross Profit | $514.52M | $424.75M | $365.56M | $303.76M | $175.70M |
| Gross Margin | 90.2% | 89.3% | 87.2% | 88.4% | 84.9% |
| Operating Income | $227.80M | $163.88M | $125.11M | $113.54M | $53.30M |
| Net Income | $223.19M | $147.58M | $112.82M | $154.78M | $50.21M |
| Net Margin | 39.1% | 31.0% | 26.9% | 45.1% | 24.3% |
| EPS | $1.19 | $0.78 | $0.58 | $0.81 | $0.12 |
Company Overview
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
1
3%
Buy / Outperform
11
35%
Hold / Neutral
17
55%
Sell / Underperform
2
6%
Analyst Consensus🔴 Bearish
12 Bullish19 Neutral/Bearish
Price Targets
$50
Average Target
↑ 15.3% Upside
Now
$19
Low
$50
Average
$90
High
Based on 40 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | Morgan Stanley | Upgrade | Overweight | $65 |
| December 9th 2025 | Barclays | Initiation | Overweight | $63 |
| November 21st 2025 | Raymond James | Upgrade | Strong Buy | $65 |
| November 13th 2025 | BMO Capital Markets | Initiation | Market Perform | $55 |
| October 27th 2025 | BofA Securities | Upgrade | Buy | $82 |
| October 10th 2025 | JP Morgan | Downgrade | Underweight | $62 |
| October 1st 2025 | Goldman | Downgrade | Sell | $64 |
| July 9th 2025 | Evercore ISI | Upgrade | Outperform | $70 |
| June 2nd 2025 | BTIG Research | Upgrade | Buy | $80 |
| February 7th 2025 | Piper Sandler | Upgrade | Overweight | $78← $31 |
| February 7th 2025 | Leerink Partners | Upgrade | Outperform | $90← $60 |
| December 20th 2024 | Stephens | Initiation | Equal Weight | $55 |
| December 4th 2024 | Mizuho | Initiation | Neutral | $55 |
| November 15th 2024 | Goldman | Initiation | Neutral | $58 |
| November 14th 2024 | Morgan Stanley | Upgrade | Equal Weight | $53← $33 |
Earnings History & Surprises
DOCSBeat Rate
100%
Last 18 quarters
Avg Surprise
+36.0%
EPS vs Estimate
Beats / Misses
18/0
Last 12 quarters
Latest EPS
$0.45
Q4 2025
EPS Surprise History
Q1 24
+26.1%
$0.29vs$0.23
Q2 24
+25.0%
$0.25vs$0.20
Q3 24
+27.3%
$0.28vs$0.22
Q4 24
+20.0%
$0.30vs$0.25
Q1 25
+45.2%
$0.45vs$0.31
Q2 25
+39.9%
$0.38vs$0.27
Q3 25
+19.4%
$0.36vs$0.30
Q4 25
+18.8%
$0.45vs$0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $0.44 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.38 | $0.45 | +18.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.30 | $0.36 | +19.4% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $0.27 | $0.38 | +39.9% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $0.31 | $0.45 | +45.2% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.25 | $0.30 | +20.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.22 | $0.28 | +27.3% | ✓ BEAT |
Q2 2024 | May 16, 2024 | $0.20 | $0.25 | +25.0% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.23 | $0.29 | +26.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $0.18 | $0.22 | +22.2% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.15 | $0.19 | +26.7% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $0.17 | $0.20 | +17.6% | ✓ BEAT |
Q1 2023 | Feb 9, 2023 | $0.18 | $0.22 | +22.2% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $0.16 | $0.17 | +6.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.10 | $0.14 | +40.0% | ✓ BEAT |
Q2 2022 | May 17, 2022 | $0.15 | $0.21 | +40.0% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $0.13 | $0.29 | +123.1% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $0.10 | $0.19 | +90.0% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $0.08 | $0.11 | +37.5% | ✓ BEAT |
Latest News
Doximity shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $62 to $65.
📈 PositiveBenzinga•Dec 15, 2025, 02:24 PM
Morgan Stanley Upgrades Doximity to Overweight, Raises Price Target to $65
📈 PositiveBenzinga•Dec 15, 2025, 01:03 PM
Barclays Initiates Coverage On Doximity with Overweight Rating, Announces Price Target of $63
📈 PositiveBenzinga•Dec 9, 2025, 03:40 PM•Also:
Doximity shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy.
📈 PositiveBenzinga•Nov 21, 2025, 08:15 PM
Raymond James Upgrades Doximity to Strong Buy, Lowers Price Target to $65
📈 PositiveBenzinga•Nov 21, 2025, 04:57 PM
BMO Capital Initiates Coverage On Doximity with Market Perform Rating, Announces Price Target of $55
➖ NeutralBenzinga•Nov 13, 2025, 09:37 AM
Canaccord Genuity Maintains Hold on Doximity, Lowers Price Target to $58
➖ NeutralBenzinga•Nov 10, 2025, 08:28 PM•Also:
Doximity falls despite Q2 beat amid uncertainty over client budgets
📉 NegativeSeeking Alpha•Nov 7, 2025, 06:46 PM
Evercore ISI Group Maintains Outperform on Doximity, Lowers Price Target to $70
➖ NeutralBenzinga•Nov 7, 2025, 02:18 PM
Doximity shares are trading lower. The company reported Q2 financial results.
📉 NegativeBenzinga•Nov 7, 2025, 01:19 PM
Doximity shares are trading lower. The company reported Q2 financial results.
📉 NegativeBenzinga•Nov 6, 2025, 10:13 PM
Doximity Raises FY2026 Sales Guidance from $628.000M-$636.000M to $640.000M-$646.000M vs $635.022M Est
📈 PositiveBenzinga•Nov 6, 2025, 09:03 PM
Doximity Sees Q3 Sales $180.000M-$181.000M vs $180.671M Est
➖ NeutralBenzinga•Nov 6, 2025, 09:03 PM
Doximity Q2 Adj. EPS $0.45 Beats $0.38 Estimate, Sales $168.525M Beat $157.614M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:02 PM
Doximity shares are trading higher after BofA Securities upgraded the stock to Buy and raised its price target to $82 from $75.
📈 PositiveBenzinga•Oct 27, 2025, 01:51 PM
B of A Securities Upgrades Doximity to Buy, Raises Price Target to $82
📈 PositiveBenzinga•Oct 27, 2025, 01:50 PM
Doximity shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and announced a $62 price target.
📉 NegativeBenzinga•Oct 10, 2025, 12:50 PM•Also:
JP Morgan Downgrades Doximity to Underweight, Announces $62 Price Target
📉 NegativeBenzinga•Oct 10, 2025, 11:43 AM•Also:
Evercore ISI Group Maintains Outperform on Doximity, Raises Price Target to $81
📈 PositiveBenzinga•Oct 8, 2025, 01:11 PM
Keybanc Maintains Overweight on Doximity, Raises Price Target to $80
📈 PositiveBenzinga•Oct 8, 2025, 12:59 PM
Frequently Asked Questions about DOCS
What is DOCS's current stock price?
Doximity, Inc. (DOCS) is currently trading at $43.65 per share. The stock has moved +0.37% today.
What is the analyst price target for DOCS?
The average analyst price target for DOCS is $70.60, based on 1 analyst.
What sector is Doximity, Inc. in?
Doximity, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NYSE exchange.
What is DOCS's market cap?
Doximity, Inc. has a market capitalization of $8.20 billion, making it a mid-cap company.
Does DOCS pay dividends?
No, Doximity, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOO
The Cooper Companies, Inc.
$82.75
Mkt Cap: $16.5B
EHC
Encompass Health Corporation
$106.39
Mkt Cap: $10.7B
EXAS
Exact Sciences Corporation
$101.82
Mkt Cap: $19.3B
GH
Guardant Health, Inc.
$99.74
Mkt Cap: $12.4B
HQY
HealthEquity, Inc.
$95.50
Mkt Cap: $8.3B
ICLR
ICON Public Limited Company
$173.77
Mkt Cap: $13.3B
RVTY
Revvity, Inc.
$96.24
Mkt Cap: $11.4B
SOLV
Solventum Corporation
$81.59
Mkt Cap: $14.2B
TEM
Tempus AI, Inc.
$64.46
Mkt Cap: $11.1B
VTRS
Viatris Inc.
$11.93
Mkt Cap: $13.7B
Explore stocks similar to DOCS for comparison